Common questions about Xiaflex (Injection) (FAQ)
Q: How long does the effect of Xiaflex typically last?
A: Studies and official information indicate that the period of observation for the change in contracture or curvature extended up to approximately one year (52 weeks) in the primary clinical trials. Data regarding the durability of the effect beyond this follow-up period is limited. Therefore, long-term effects are not fully established.
Q: Will I need multiple treatments of Xiaflex?
A: The official treatment protocol is structured as a course of therapy that may require multiple injections. Regulatory documents state that for Dupuytren's contracture, up to three injections may be administered per cord. For Peyronie's disease, the treatment involves up to four total cycles per plaque.
Q: What should I do if the swelling doesn't go away after a few days?
A: Official patient safety information states that contact with a healthcare provider is appropriate if any localized reactions, such as swelling or bruising, become worse or if you have concerns that they are not resolving as expected. While swelling is very common, professional guidance may be appropriate if the reaction is concerning.
Q: How quickly do people typically notice a change after the injection?
A: The initial physical effect of the enzyme is closely tied to the required follow-up procedure. This procedure, which physically reduces the restriction caused by the tissue, is performed by the healthcare provider within 24 to 72 hours after the injection.
Q: Is it possible for the condition to come back after being treated with Xiaflex?
A: Clinical studies noted that the long-term effects regarding the possibility of recurrence are not fully established. This is due to limited follow-up data being available beyond the initial observation period of the primary registration trials.
Q: Can Xiaflex be used if I have had prior surgery for the condition?
A: Specific clinical criteria state that treatment should not be administered to a patient who has received surgical treatment on the affected joint or area within a defined period prior to the injection. After that period has passed, the question of eligibility can be addressed.
Q: Is Xiaflex a permanent solution?
A: Official regulatory documents indicate that the long-term effects of the treatment have not been established beyond the study follow-up period. Because recurrence is a possibility, the long-term data limitation means a conclusion of permanent treatment cannot be made.
Q: Is Xiaflex used for any other conditions besides the approved ones?
A: Xiaflex is indicated in official regulatory documents only for the treatment of adult patients with Dupuytren's contracture who have a palpable cord and adult men with Peyronie's disease who have a palpable plaque and specific curvature. Other uses are not mentioned in the product's official labeling.
Q: How does Xiaflex differ from surgery for Dupuytren's contracture or Peyronie's disease?
A: Xiaflex is described as a non-surgical, intralesional injection treatment that works using an enzyme to chemically break down the restrictive collagen. This differs from surgery, which typically involves the physical removal or cutting of the abnormal tissue.
Q: Can Xiaflex affect my ability to drive or operate machinery?
A: Official adverse reaction sections list temporary effects such as dizziness or fainting which are documented as potential side effects. These effects may temporarily affect a patient’s alertness and concentration.
Q: Are there any long-term side effects associated with Xiaflex use?
A: The known adverse events are those reported during the controlled clinical trials. Regulatory documents state that data is limited regarding long-term side effects beyond the trial follow-up periods.
Q: Does Xiaflex contain any ingredients I might be allergic to?
A: The medicine is contraindicated, meaning its use is restricted, in patients with a known history of allergy to the active ingredient or any other collagenase product. The complete list of excipients (inactive ingredients) is available from the healthcare provider or pharmacist.
Q: What if I miss one of the scheduled treatment visits?
A: The official treatment protocol requires strict adherence to the prescribed intervals, which are approximately four or six weeks apart. Because the cyclic schedule is a fundamental component of the treatment regimen, making adherence to the prescribed interval important.
Q: Are there any specific activities I should avoid after the injection?
A: The official label contains a specific restriction on sexual activity between the first and second injections of a treatment cycle for Peyronie's disease. For both conditions, activity limitations are advised to protect the injected area and to avoid undue strain.
Q: Is Xiaflex considered a chemotherapy drug?
A: No. Xiaflex is classified pharmacologically as an enzyme and a biologic product. This means it is a type of protein that accelerates chemical reactions to break down tissue and is not classified as a chemotherapy drug.
Q: How does Xiaflex affect blood pressure?
A: Official patient safety information notes that low blood pressure is listed as a possible symptom of a severe allergic, or hypersensitivity, reaction. This is documented as a potential serious adverse event that is noted in the official patient information.
Q: Why do some people need two injections while others only need one?
A: The number of required injections depends on the patient's response and the treatment goals. Subsequent treatment cycles are considered if the contracture or curvature remains above a specified, clinically defined threshold after the preceding treatment cycle.
Q: Is the drug approved outside of the United States?
A: Yes, the drug has been approved for use by regulatory bodies outside of the United States. This includes the European Medicines Agency (EMA) and Health Canada, among others.
Q: Are there restrictions on who can administer the Xiaflex injection?
A: Regulatory documents require the injection to be administered by a healthcare professional with experience in the specific intralesional injection procedure for either Dupuytren's contracture or Peyronie's disease.
Q: Do I need to do physical therapy after the Xiaflex treatment?
A: Official regulatory instructions describe specific required post-procedure activities. This includes required follow-up procedures like passive finger extension or penile modeling, along with specific required at-home exercises and potential splinting.
Q: Are there studies about Xiaflex use in women?
A: Clinical trials for Dupuytren’s contracture included adult patients of both sexes. However, studies supporting the use for Peyronie's disease were conducted only in adult men.
